You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》高盛上調藥明生物(02269.HK)目標價至178.6元 評級「買入」
阿思達克 11-02 10:01
高盛發表研究報告指出,該行與藥明生物(02269.HK)管理層就其第三季營運進行電話會議,管理層重申其長期戰略,並對2021及2022財年的盈利指引由按年增長65%及40%,上調至增長75%及45%,部分由於來自疫情相關項目的強勁需求(2021及2022財年收入預測分別爲30億及20億元人民幣),2020至2025財年的年均複合增長率爲40%,並預期將於2022財年起實現正自由現金流。 該行又稱,藥明生物透露在第三季新增兩個商業項目,包括一個全球製藥商對外授權的商業項目,相信利好其服務能力和業績。重申對其「買入」評級(確信買入名單),並對其2021至2023財年的盈利預測分別上調5.2%、8.9%及4.7%,以反映更新後的盈利指引,目標價由170.7元上調至178.6元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account